Calstang, You are correct. The discussion be
Post# of 144863
You are correct.
The discussion between Closetinvsetor and JLang today addresses this.
With an expected limited supply of leronlimab, reserving its use for severe/critical Covid seems the appropriate approach over the short term.
The Patterson assay, to identify critically dysregulated patients, in advance of clinical decompensation, seems like a great solution while Cytodyn arranged for the tens of millions of doses needed eventually.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)